Heart failure.
McKelvie
Robert
R
McMaster University, Hamilton, Ontario, Canada.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D017147:Defibrillators, Implantable; D004077:Digoxin / Q000627:therapeutic use; D015444:Exercise; D006333:Heart Failure / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists; D014859:Warfarin / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D000451:Mineralocorticoid Receptor Antagonists; D014859:Warfarin; D004077:Digoxin; D001241:Aspirin